Mark J. Niciu M.D., Ph.D.
Assistant Professor of Psychiatry & Iowa Neuroscience Institute
Iowa University Hospitals and Clinics/Carver College of Medicine
200 Hawkins Dr.
W267 GH
Iowa City, IA 52242
Tel.#: (860)-748-8115 (cell), (319)-356-1549 (office), (319)-353-8656 (fax)
E-mail: mark-niciu@uiowa.edu; mark.niciu@gmail.com

Education:

Level	Institution	Location	Dates	Degree Conferred
College	Manhattan College	Riverdale, NY	08/95-05/99	B.S., Biology, Philosophy
Medical/Graduate School	University of Connecticut Health Center	Farmington, CT	07/00-05/08	M.D., Ph.D. (Sun., 05/18/2008 graduation)

Training:

Level	Institution	Location	Dates	Degree Conferred
Residency	Yale University Dept. of Psychiatry	New Haven, CT	07/08-06/12	N/A (ABPN Board Certified 9/12)
	Yale's Neuroscience Research Training Program (NRTP)	New Haven, CT	07/10-06/12	N/A
Fellowship	National Institutes of Health/National Institute of Mental Health Experimental Therapeutics and Pathophysiology Branch	Bethesda, MD	07/12-02/18	N/A

Summary Statement:

I am an Assistant Professor in the Department of Psychiatry and Iowa Neuroscience Institute at the University of Iowa Health Care. My clinical and translational research program is dedicated to the pathophysiology and experimental therapeutics of major mood disorders, especially treatment-resistant major depressive disorder (MDD) and bipolar disorder. A major aim is the identification, replication, and dissemination of treatment response biomarkers of glutamate-based therapies. As an example, our group has identified treatment-resistant depressed subjects with a family history of an alcohol use disorder in a first-degree relative have a greater and more sustained antidepressant response to racemic ketamine infusion. On the clinical end, we are currently studying alcohol-sensitive multimodal, e.g. psychological, neurophysiological, and neuroimaging, biomarkers to predict antidepressant response with greater sensitivity and specificity than family history alone (https://clinicaltrials.gov/study/NCT02122562). I am also principal investigator on the University of Iowa's Interventional Psychiatry Service Patient Registry, investigating multimodal treatment response biomarkers to available treatment modalities including es/ketamine and transcranial magnetic stimulation (TMS) (https://clinicaltrials.gov/study/NCT04480918). Finally, in the Iowa Psychedelic Research Program, I am co-principal investigator (with Peg Nopoulos M.D.). We have completed a pilot randomized active comparator trial of ketamine-assisted vs. psilocybin-assisted psychotherapy in alcohol use disorder (https://clinicaltrials.gov/study/NCT05421065). Our larger, currently

philanthropically funded trial with a targeted enrollment of n=80 is currently recruiting (https://clinicaltrials.gov/study/NCT06405607).

Please see the following PubMed link (for a listing of peer-reviewed publications) and Google Scholar page:
https://www.ncbi.nlm.nih.gov/pubmed/?term=niciu+m
http://scholar.google.com/citations?user=OYRntY0AAAAJ&hl=en

H-index: 47 (as of 16 November 2026)

Specialties: psychiatry, clinical neuroscience, major depressive disorder, bipolar disorder, substance-induced mood disorders, alcohol use disorder, ketamine, glutamate, experimental therapeutics

Skills:

Techniques: Perfusion-fixation (postnatal, adult mice), Cryosectioning, Immunohistochemistry, Immunocytochemistry, Confocal Microscopy, Immunoblotting, Radioimmunoassays, Peripheral Blood Mononuclear Cell Isolation, *In vitro* cell culture (including stem cells)

Software: Microsoft Applications (MS Word, Excel, Power Point), SPSS

Bibliography:

Published/Accepted Primary Research Articles in Peer-Reviewed Journals

1. Mair GR, **Niciu MJ,** Stewart MT, Brennan G, Omar H, Halton DW, Mains RE, Eipper BA, Maule AG, Day TA (2004) A functionally atypical amidating enzyme from the human parasite *Schistosoma mansoni*. *FASEB J* **18**(1):114-121; PMID: 14718392
2. **Niciu MJ**, Ma X-M, El Meskini R, Ronnett GV, Mains RE, Eipper BA (2006) Developmental changes in the expression of ATP7A during a critical period in postnatal neurodevelopment. *Neuroscience* **139**(3):947-964; PMID: 16549268
3. **Niciu MJ**, Ma X-M, El Meskini R, Patcher JS, Mains RE, Eipper BA (2007) Altered ATP7A expression and other compensatory responses in a murine model of Menkes disease. *Neurobiol Dis* **27**(3):278-291 (image selected for journal cover); PMID: 17588765
4. **Niciu MJ,** Chan G, Gelernter J, Arias AJ, Douglas K, Brady K, Weiss R, Anton RF, Farrer L, Cubells JF, Kranzler HR (2009) Subtypes of major depression in substance dependence. *Addiction* **104**(10):1700-9; PMID: 19681804
5. Anticevic A, Gancsos M, Murray JD, Repovs G, Dreisen NR, Ennis DJ, **Niciu MJ**, Morgan PT, Surti TS, Smith M, Wang X-J, Krystal JH, Corlett PR (2012) NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. *Proc Natl Acad Sci U.S.A.* **109**(41):16720-5; PMID: 23012427
6. Zeng M, **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Franco-Chaves J, Brutsche NE, Zarate CA Jr (2012) Acute stress symptoms do not worsen in PTSD and abuse with a single subanesthetic dose of ketamine. *Biol Psychiatry* **73**(12):e37-8; PMID: 23245747
7. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr (2013) Subanesthetic dose ketamine does not induce an affective switch in three independent samples of treatment-resistant depression. *Biol Psychiatry* **74**(10):e23-4; PMID: 23726512
8. **Niciu MJ**, Grunschel BD, Corlett PR, Pittenger C, Bloch MH (2013) Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder. *J Psychopharmacol* **27**(7):651-4; PMID: 23676198
9. Esterlis I, Bois F, Pittman B, Picciotto MR, Shearer L, Anticevic A, Carlson J, **Niciu MJ**, Cosgrove KP, D'Souza DC (2014) *In vivo* evidence for β_2*-nAchR upregulation in smokers as compared to nonsmokers with schizophrenia. *Biol Psychiatry* **76**(6):495-502; PMID: 24360979
10. Luckenbaugh DA, **Niciu MJ**, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA Jr (2014) Do the dissociative side effects of ketamine mediate its antidepressant effects? *J Affect Disord* **159**:56-61; PMID: 24679390
11. Svenningsson P, Berg L, Mathews D, Ionescu DF, Richards EM, **Niciu MJ**, Malinger A, Toups M, Manji H, Zarate CA Jr, Greengard P (2014) Preliminary evidence that early reduction in p11

levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. *Mol Psychiatry* **19**(9):962-4; PMID: 24614495

12. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Brutsche NE, Nolan NM, Zarate CA Jr (2014) Clinical predictors of ketamine response in treatment-resistant major depression. *J Clin Psychiatry* **75**(5):e417-23; PMID: 24922494
13. Lundin NB, **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Zarate CA Jr (2014) Baseline vitamin B12 and folate levels do not predict improvement in bipolar depression after a single infusion of ketamine. *Pharmacopsychiatry* **47**(4-5):141-4; PMID: 24955551
14. Abdallah CA*, **Niciu MJ* (co-first author)**, Fenton LR, Fasula MK, Rothman, DL, Mason GF, Black A, Krystal JH, Sanacora, G (2014) Decreased occipital cortical glutamate levels in response to cognitive-behavioral therapy and pharmacotherapy in major depressive disorder. *Psychother Psychosom* **83**(5):298-307; PMID: 25116726
15. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort, JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr (2014) Riluzole likely lacks antidepressant efficacy in ketamine non-responders. *J Psychatr Res* **58**:197-9; PMID: 25139008
16. Ballard ED, Ionescu DF, Vande Voort JL, **Niciu MJ**, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey ML, Zarate CA Jr (2014) Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. *J Psychatr Res* **58**:161-6; PMID: 25169854
17. Ionescu DF, Luckenbaugh DA, **Niciu MJ**, Richards EM, Slonena EE, Vande Voort JL, Brutsche N, Zarate CA Jr (2014) Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. *J Clin Psychiatry* **75**(9):e932-8; PMID: 25295436
18. Ionescu DF, Luckenbaugh DA, **Niciu MJ**, Richards EM, Zarate CA Jr (2014) A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. *Bipolar Disord* **17**(4):438-43; PMID: 25400146
19. Ortiz R, **Niciu MJ**, Lukahati N, Saligan LN, Nugent AC, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr (2014) SHANK3 as potential biomarker of ketamine's antidepressant effects and its neural correlates in bipolar depression. *J Affect Disord* **172C**:307-11; PMID: 25451430
20. **Niciu, MJ**, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ML, Zarate CA Jr (2014) Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. *Int J Neuropsychopharmacol* **18**(1); PMID: 25539512
21. Ionescu DF, Nugent AC, Luckenbaugh DA, **Niciu MJ**, Richards EM, Zarate CA Jr, Furey ML (2015) Baseline working memory deficits in dimensional anxious depression as detected by magnetoencephalography. *Acta Neuropsychiatrica*, **27**(3):143-52; PMID: 25600154
22. Lally N, Nugent AC, Luckenbaugh DA, **Niciu MJ**, Roiser JP, Zarate CA Jr (2015) Neural correlates of change in in major depressive disorder anhedonia following open-label ketamine. *J Psychopharmacol* **29**(5):596-607; PMID: 25691504
23. Lally N, An L, Banerjee D, **Niciu MJ**, Luckenbaugh DA, Richards EM, Rosier JP, Shen J, Zarate CA Jr, Nugent AC (2015) Reliability of 7T (1) H-MRS measured human prefrontal cortex glutamate, glutamine and glutathione signals used n adapted echo time optimized PRESS sequence: A between- and within-session investigation. *J Magn Reson Imaging* **43**(1):88-98; PMID: 26059603
24. Xu AJ, **Niciu MJ**, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr (2015) Lithium and valproate levels do not correlate with ketamine's antidepressant efficacy in treatment-resistant bipolar depression. *Neural Plast* **2015**:858251; PMID: 26137324
25. Ballard ED, Luckenbaugh DA, Richards EM, Walls T, Brutsche N, Ameli R, **Niciu MJ**, Vande Voort JL, Zarate CA Jr (2015) Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. *J Psychiatr Res* **68**:68-73; PMID: 26228403
26. **Niciu MJ* (co-first author)**, Abdallah CG*, Fenton LR, Fasula MK, Jiang L, Black A, Rothman DL, Mason GF, Anderson GM, Sanacora G (2015) A history of early life loss correlates with

successful cognitive-behavioral therapy in major depressive disorder. *J Affect Disord* **187**:241-44; PMID: 26363143

27. Richards EM, Mathews DC, Machado-Vieira R, **Niciu MJ**, Ionescu DF, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Smith MA, Luckenbaugh DA, Zarate CA Jr (2016) A randomized, placebo controlled trial of the delta opioid agonist AZD2327 in anxious major depressive disorder. *Psychopharmacol (Berl)* **233**(6):1119-30; PMID: 26728893
28. Machado-Vieira R, Gold PW, Luckenbaugh DA, Ballard ED, Richards EM, Henter ID, De Sousa RT, **Niciu MJ**, Yuan P, Zarate CA Jr. (2016) The role of adipokines in the rapid antidepressant effect of ketamine. *Mol Psychiatry* **22**(1):127-133; PMID: 27046644
29. Ballard ED, Vande Voort JL, Bernert RA, Luckenbaugh DA, Richards EM, **Niciu MJ**, Furey ML, Duncan WC Jr, Zarate CA Jr (2016) Nocturnal wakefulness is associated with next-day suicidal ideation in major depression and bipolar disorder. *J Clin Psychiatry* **77**(6): 825-31; PMID: 27337418
30. Fujita M, Richards EM, **Niciu MJ**, Ionescu DF, Zoghbi SS, Hong J, Telu S, Hines CS, Pike VW, Zarate CA Jr, Innis RB (2016) cAMP signaling in brain is decreased in unmedicated depressed patients and increased by treatment with a selective serotonin reuptake inhibitor. *Mol Psychiatry* **22**(5):754-759; PMID: 27725657
31. Pennybaker SJ, **Niciu MJ**, Luckenbaugh DA, Zarate CA Jr (2016) Symptomatology and predictors of antidepressant response in extended responders to a single ketamine infusion. *J Affect Disord* **208**:560-566; PMID: 27839782
32. Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, **Niciu MJ**, Park LT, Machado-Vieira R, Duncan WC Jr, Zarate CA Jr (2016) Antisuicidal response following ketamine infusions is associated with decreased nighttime wakefulness in treatment resistant depression. *J Clin Psychiatry* **78**(8):1068-1074; PMID: 27929610
33. Ballard ED, Vande Voort JL, Bernert RA, Luckenbaugh DA, Richards EM, **Niciu MJ**, Furey ML, Duncan WC Jr, Zarate CA Jr. (2016) Correction: nocturnal wakefulness is associated with next-day suicidal ideation in major depression and bipolar disorder. *J Clin Psychiatry* **77**(12):e1655; PMID: 28086017
34. Ballard ED, Wills K, Lally N, Richards EM, Luckenbaugh DA, Walls T, Ameli R, **Niciu MJ**, Brutsche NE, Park L, Zarate CA Jr (2017) Anhedonia as a clinical correlate of suicidal thoughts in ketamine clinical trials. *J Affect Disord* **218**:195-200; PMID: 28477497
35. Kadriu B, Gold PW, Luckenbaugh DA, Lener MS, Ballard ED, Niciu MJ, Park LT, De Sousa RT, Yuan P, Machado-Vieira R, Zarate CA Jr (2017) Acute ketamine administration corrects abnormal inflammatory bone markers in major depression. *Mol Psychiatry* Epub ahead of print 30 May; PMID: 28555075
36. **Niciu MJ**, Iadarola ND, Banerjee D, Luckenbaugh DA, Ionescu DF, Park M, Lener M, Park L, Ballard ED, Brutsche NE, McMahon F, Machado-Vieira R, Nugent AC, Zarate CA Jr (2017) The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder. *J Psychopharmacol* **31**(12):1570-1577; PMID: 29039254
37. Ballard ED, Yarrington J, Farmer CA, Lener MS, Kadriu B, Lally N, Williams D, Machado-Vieira R, **Niciu MJ**, Park L, Zarate CA Jr. (2017) Parsing the heterogeneity of depression: Factor analysis across commonly used depression rating scales. *J Affect Disord* **231**:51-57; PMID: 29448238
38. **Niciu MJ**, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard ED, Zarate CA Jr (2018) Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant major depression. *J Affect Disord* **232**:310-325; PMID: 29501990
39. Kadriu B, Ballard ED, Nugent AC, Park L, Lener M, **Niciu MJ**, Henn F, Henter I, Yazdian A, Park M, Yuan S, Zarate CA Jr., Farmer C (2018) Clinical trial of the potassium channel activator diazoxide for major depressive disorder halted due to intolerability. *J Clin Psychopharmacol* 38(3):243-246; PMID: 29601316
40. Boggs DL, Surti T, Gupta A, Gupta S, **Niciu M**, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Raganathan M (2018) The effects of cannabidiol (CBD) on cognition

and symptoms in outpatients with chronic schizophrenia: a randomized placebo-controlled trial. *Psychopharmacol* **235**(7):1923-1932; PMID: 29619533

41. Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, Machado-Vieira R, Yuan P, **Niciu MJ**, Lyoo CH, Henter ID, Salvadore G, Drevets WC, Kolb H, Innis RB, Zarate CA Jr. (2018) PET radioligand binding to translocator protein (TSPO) is selectively increased in unmedicated depressed subjects. *EJNMMI Res* **8**(1):57; PMID: 29971587
42. Ballard ED, Yarrington J, Farmer CA, Richards EM, Machado-Vieira R, Kadriu B, **Niciu MJ**, Yuan P, Park L, Zarate CA Jr. (2018) Characterizing the course of suicidal ideation response to ketamine. *J Affect Disord* **241**:86-93; PMID: 300099268
43. Alario AA, Pace BD, **Niciu MJ,** Trapp NT (2023) Transcranial magnetic stimulation induces heart rate decelerations independent of treatment outcome. *Brain Stim* (4):1044-1046; PMID: 37356567
44. Wang R, Khan KM, Balasubramanian N, James T, Selvakumar GP, Kim D, Pierson S, Wu Q, **Niciu MJ**, Hefti MM, Marcinkiewcz CA (2023) Alcohol inhibits sociability via serotonin inputs to the nucleus accumbens. *bioRxiv* **2023**.05 29.542761, PMID: 37398335
45. Marcinkiewcz C, Wang R, Khan K, Balasubramanian N, James T, Pushpavathi S, Kim D, Piersn S, Wu Q, **Niciu M**, Hefti M (2023) Alcohol inhibits sociability via serotonin inputs to the nucleus accumbens. *Res Sq* **rs.3**.rs-2992781, PMID: 37461716
46. Alario AA, Pace BD, **Niciu MJ**, Trapp NT (2024) Transcranial magnetic stimulation-associated heart rate decelerations attenuate after a TMS treatment course for depression. *Brain Stim* S1935-861X(24)00165-7, PMID: 39341590

Submitted Manuscript(s)

1. **Niciu MJ**, Golden LE, Mostek AB, Freedburg MV, Flaum MA, Wilton AE, Streeter J, Maurer CR, Ventullo AK, Stinson RD, Furhmeister LA, Nopoulos PC (2026) Challenging expectancy bias and nocebo response in psychedelic research: a pilot study of ketamine-assisted and psilocybin-assisted psychotherapies in alcohol use disorder. In review at *Psychiatric Research and Clinical Practice*.

Manuscript(s)-in-Preparation

1. Alario AA, Sumner RL, **Niciu MJ***, Trapp, NT* (2026) Measuring changes in visual evoked potentials associated with rTMS for depression. To be submitted at journal to be determined
2. (Final Author List/Position TBD) (2025) Investigation of predictive factors of response and antidepressant response transcranial magnetic stimulation with the NIH Toolbox Emotion Battery. To be submitted at journal to be determined

Published/Accepted Non-Primary Research Articles, e.g. Reviews and Commentaries, in Peer-Reviewed Journals

1. **Niciu MJ**, Kelmendi B, Sanacora G (2012) Overview of glutamatergic neurotransmission in the nervous system. *Pharmacol Biochem Behav* **100**(4):656-64; PMID: 21889952
2. **Niciu MJ,** Petrakis IL (2012) What's new in alcohol disorders: practical tips from new research. *Psychiatric Times,* September 2012 edition.
3. **Niciu MJ,** Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr (2013) Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action: part I. major depressive disorder. *CNS Spectr* **18**(5):231-41; PMID: 23462230
4. **Niciu MJ,** Ionescu DF, Mathews DC, Richards EM, Zarate CA Jr (2013) Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action: part II. bipolar disorder. *CNS Spectr* **18**(5):242-51; PMID: 23472710
5. Ionescu DF, **Niciu MJ**, Mathews DC, Richards EM, Zarate CA Jr (2013) Neurobiology of anxious depression: a review. *Depress Anxiety* **30**(4):374-85; PMID:23495126
6. Ionescu DF, **Niciu MJ**, Henter ID, Zarate CA Jr (2013) Defining anxious depression: a review of the literature. *CNS Spectr* **18**(5):252-60; PMID: 23507190

7. **Niciu MJ,** Arias AJ (2013) Targeted opioid receptor antagonists in the treatment of alcohol use disorders. *CNS Drugs* **27**(10):777-87; PMID: 23881605
8. **Niciu MJ**, Henter ID, Sanacora G, Zarate CA Jr. (2014) Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity? *World J Biol Psychiatry* **15**(1):2-16, PMID: 2402876
9. Mathews DC, Richards EM, **Niciu MJ**, Ionescu DF, Rasimas JJ, Zarate CA Jr (2013) Neurobiological aspects of suicide or suicide attempts in bipolar disorder. *Transl Neurosci* **4**(2):203-16, PMID: 24294519
10. **Niciu MJ**, Ionescu DF, Richards EM, Zarate CA Jr. (2014) Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. *J Neural Transm* **121**(8):907-24, PMID: 24318540
11. **Niciu MJ**, Mathews DC, Nugent AC, Ionescu DF, Furey ML, Richards EM, Machado-Vieira R, Zarate CA (2014) Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants. *Depress Anxiety* **31**(4): 297-307: PMID: 24353110
12. **Niciu MJ**, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DL (2014) Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. *Ann Rev Pharmacol Toxicol* **54**:119-39, PMID:24392693
13. **Niciu MJ,** Mason GF (2014) Neuroimaging in alcohol and drug dependence. *Curr Behav Neurosci Report* **1**(1):45-54, PMID: 24678450
14. Ionescu DF, **Niciu MJ,** Richards EM, Zarate CA Jr (2014) Pharmacological treatment of dimensional anxious depression: a review. *Prim Care Companion CNS Disord* **16**(3):, PMID: 25317369
15. **Niciu MJ**, Mathews DC, Ionescu DF, Richards EM, Furey ML, Yuan P, Nugent AC, Henter ID, Machado-Vieira R, Zarate CA Jr (2014) Biomarkers in mood disorders: developing new and improved therapeutics. *Rev Psiquiatr Clin (Arch Clin Psychiatry)* **41**(5):131-4, PMID: 26082563
16. Hammond CJ, **Niciu MJ**, Drew S, Arias AJ (2015) Anticonvulsants for the treatment of alcohol withdrawal and alcohol use disorders. *CNS Drugs* **29**(4):293-311, PMID: 25895020
17. Iadarola ND, **Niciu MJ**, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent AC, Machado-Vieira R, Zarate CA Jr (2015) Ketamine and other NMDA receptor antagonists in the treatment of depression: a perspective review. *Ther Adv Chron Dis* **6**(3):97-114, PMID: 25954495
18. Zarate CA Jr, **Niciu MJ** (2015) Ketamine for depression: evidence, promise and challenges. *World Psychiatry* **14**(3):348-50, PMID: 26407791
19. Park M, **Niciu MJ** and Zarate CA Jr (2015) Novel glutamatergic treatments for severe mood disorders. *Curr Behav Neurosci Rep* **2**(4):198-208, PMID: 26824031
20. Jaso B, **Niciu MJ**, Iadarola ND, Lally N, Richards EM, Park M, Ballard ED, Nugent AC, Machado-Vieira R, Zarate CA Jr (2016) Therapeutic modulation of glutamate receptors in major depressive disorder. *Curr Neuropharmacol* **15**(1):57-70, PMID: 26997505
21. Lener MS, **Niciu MJ**, Ballard ED, Park M, Park LT, Nugent A, Zarate CA Jr (2016) Glutamate and GABA systems in the pathophysiology of major depression and antidepressant response to ketamine. *Biol Psychiatry* **81**(10):886-897; PMID: 27449797
22. Comstock SM, Vaidya JG, **Niciu MJ** (2019) Differential drug response and neurophysiological correlates in subjects with a family history of an alcohol use disorder. *Chronic Stress (Thousand Oaks)* **3**:247054701986526; PMID: 31511840
23. Alario AA and **Niciu MJ** (2021) Biomarkers of Ketamine's Antidepressant Effect: A Clinical Review of Genetics, Functional Connectivity, and Neurophysiology. *Chronic Stress (Thousand Oaks)* **5**:24705470211014210; PMID: 34159281
24. Alario AA and **Niciu MJ** (2022) (Es)ketamine for suicidal ideation and behavior: clinical efficacy. *Chronic Stress (Thousand Oaks)*, 6:24705470221128017, PMID: 36276228
25. Sandoval SO, Cappuccio G, Kruth K, Osenberg S, Khalil S, Mendez-Albelo N, Padmanabhan K, Wang D, **Niciu MJ**, Bhattacharyya A, Stein J, Sousa AMM, Waxman E, Buttermore E, Whye D, Sirois CL, Cross-IDDRC Human Stem Cell Consortium, Williams A, Maletic-Savatic M, Zhao X (2024) Rigor and reproducibility in human brain organoid research: where we are and where we need to go. *Stem Cell Rep* **19**(6)796-816, PMID: 38759644

26. **Niciu MJ**, Mesiner R, Carr BR, Farooqui AA, Feifel D, Kaplin A, Kendrick EJ, Kim PM, Scheck CD, Vande Voort, JL, Parikh SV (2024) National Network of Depression Centers Position Statement: Insurance Coverage for Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder. *J Affect Disord* **346**:221-222, PMID: 37940059
27. Lewis BR, Reid MJ, Novick AM, Bryne K, **Niciu MJ**, Fonzo GA, Meyer TD, Feifel D, El-Mallakh RS, Soares J, Suppes T, Barrett FS (2026) Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the Nartional Network of Depression Centers' task group on psychedelics and related compounds. *J Psycopharmacol* 5:2698811251413490, PMID: 41645048

Submitted Review(s)
(none)

Review(s)-in-Preparation
1. Alario AA, **Niciu MJ** (2026) (Es)ketamine for suicidal ideation and behavior: predictors/correlates of response. *Chronic Stress (Thousand Oaks)*, in preparation
2. Buse E, Guiler W, Brandt E, Assimacopoulos E, **Niciu MJ** (2026) Investigational NMDA-receptor modulators for the treatment of major depressive disorder. *J Exp Pharmacol*, in preparation
3. Galeazzi FM, Guiler W, Gaine M, **Niciu MJ** (2026) MicroRNAs in depression: towards a mechanistic understanding and the potential impact of ketamine treatment, Journal TBD, in preparation

Published/Accepted Book Chapters and Other Monographs
1. **Niciu MJ**, Mains RE, Eipper BA "Peptide Amidation" in *The Encyclopedia of Biological Chemistry, Volume 3;* St. Louis: Academic Press/Elsevier Science, 2004, pp. 226-230
2. **Niciu MJ** "Eating Disorders" in Stead LG, Kaufman MS, Yanofski J (eds.) *First Aid for the Psychiatry Clerkship: A Student-to-Student Guide, 3rd edition*; New York: McGraw-Hill Medical, 2011, pp. 145-151
3. **Niciu MJ** (2012) First, Do No Harm: My Dual Obligation as Psychiatric Resident and Aspiring Clinical Researcher, *Am J Psychiatry Resident's Journal*, November 2012 (online only)
4. **Niciu MJ** (2013) Book Review: Neuroimaging in Addiction. (2011) Byron Adinoff and Elliot A. Stein, Eds. Hoboken, NJ: John Wiley & Sons, Ltd., 420 pp. *J Nerv Ment Dis* **201**(5):444
5. **Niciu MJ**, Sinclair CM, Shelton RE, Zarate CA Jr "Treatment of Depressive Disorders" in *Gabbard's Treatments of Psychiatric Disorders*, 5th edition, Arlington (VA): American Psychiatric Publishing, 2014, pp. 275-301
6. **Niciu MJ** (2014) Family history of an alcohol use disorder and ketamine's antidepressant efficacy in major depression. *Am J Psychiatry Resident's Journal*, October 2014 (online only)
7. Ballard ED, Richards EM, Ionescu DF, **Niciu MJ**, Vande Voort J, Zarate CA Jr "Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior" in Cannon KE and Hudzik TJ (eds.) *Suicide: Phenomenology and Neurobiology,* Switzerland: Springer International Publishing, 2014, pp. 209-223
8. Decker AR, Bacalzo B, and **Niciu MJ**, "Glutamate-Based Preclinical and Clinical Dysfunction in Bipolar Disorders" in Machado-Vieira, R and Soares JC (eds.) *Biomarkers in Bipolar Disorders*, Elsevier Publishing, 2021, pp. TBD

Submitted Books Chapters and Other Monographs
(none)

Meeting Seminars
1. **Niciu MJ**, Ma X-M, El Meskini R, Mains RE, Eipper BA "Mutant ATP7A Expression and Impaired Cuproenzyme Activity in a Murine Model of Menkes Disease" Seminar presented at

the American Society of Neurochemistry 37th Annual Meeting from 11-15 March 2006 in Portland, OR, U.S.A. [abstract also published in *J Neurochem* **96**(Suppl. 1):97]

2. **Niciu MJ** "Rapid and Sustained Antidepressant Effects of Ketamine: Therapeutic Implications" Seminar presented on 16 June 2013 at the College on Problems in Drug Dependence (CPDD) 75th Annual Meeting in San Diego, CA, U.S.A.
3. **Niciu MJ** "Ketamine and Family History of an Alcohol Use Disorder: Strange Bedfellows in Treatment-Resistant Depression." Seminar presented on 5 December 2016 at the American College of Neuropsychopharmacology (ACNP) 55th Annual Meeting in Hollywood, FL, U.S.A.
4. **Niciu MJ** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression." Seminar presented on 7 April 2017 at the Anxiety and Depression Association (ADAA)'s Anxiety and Depression Conference 2017 in San Francisco, CA, U.S.A.
5. **Niciu MJ** "Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression." Seminar presented on 7 April 2018 at the Anxiety and Depression Association (ADAA)'s Anxiety and Depression Conference 2018 in Washington, DC, U.S.A.
6. **Niciu MJ**, "Ketamine for Treatment-Resistant Depression." Seminar presented on 16 November 2018 at the 2018 NAMI Iowa Annual Conference in Des Moines, IA, U.S.A.
7. **Niciu MJ,** "Mood Implications of the COVID-19 Pandemic: Is There a Place for Es/ketamine?" Iowa Physiological Society Annual Society (Keynote Seminar), 10 December 2021, Virtual (Des Moines, IA, U.S.A.)
8. **Niciu MJ,** "Es/ketamine as a Rapid-Acting Antidepressant in Treatment-Resistant Depression." Seminar presented on 12 September 2022 at the 2022 Midwest Association of Forensic Scientists (MAFS) Annual Conference in Des Moines, IA , U.S.A.
9. **Niciu MJ**, Meisner, RC, Parikh SV "Ketamine: Weighing the Risks and Rewards of Ketamine Treatment." Seminar presented on 20 September 2022 at the National Network of Depression Centers (NNDC) 14th Annual Conference in Ann Arbor, MI, U.S.A.
10. **Niciu MJ** "Es/ketamine in Treatment-Resistant Depression." Seminar presented on 7 October 2022 at the 2022 Iowa Psychiatric Physicians Society (IPPS) Post Graduate Fall Symposium in Coralville, IA, U.S.A.
11. **Niciu, MJ** "Es/ketamine in Treatment-Resistant Depression." Seminar presented on 18 March 2023 at the 2023 Psychiatric Society of Virginia Spring Symposium in Richmond, VA, U.S.A.

Meeting Posters/Abstracts

1. **Niciu MJ,** Mains RE, Eipper BA "Neuronal ATP7A, peptidylglycine α-amidating monooxygenase (PAM) and amidated neuropeptides in a murine model of Menkes disease," Poster presented 25-27 April 2003 at the American Society for Clinical Investigation (ASCP) /Association of American Physicians (AAP) Joint Meeting, Chicago, IL, U.S.A.
2. **Niciu MJ**, Mains RE, Eipper BA "Neuronal ATP7A, peptidylglycine α-amidating monooxygenase (PAM) and amidated neuropeptides in a murine model of Menkes disease," Poster presented 8-12 June 2003 at Neuropeptides 2003 Summer Conference, Montauk, NY, U.S.A.
3. **Niciu MJ**, Mains RE, Eipper BA "Neuronal ATP7A, peptidylglycine α-amidating monooxygenase (PAM) and amidated neuropeptides in a murine model of Menkes disease," Poster presented July 2003 at National M.D./Ph.D. Student Conference, Snowmass, CO, U.S.A.
4. Nugent AC, **Niciu MJ**, Marquardt C, Holroyd T, Salvadore G, Furey ML, Zarate CA Jr "Working Memory Abnormalities in Active Bipolar Depression as Detected as Magnetoencephalography," Poster presented 2-6 December 2012 at American College of Neuropsychopharmacology (ACNP) 51st Annual Meeting, Hollywood, FL U.S.A.
5. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Mathews DC, Richards EM, Ibrahim L, DiazGranados N, Brutsche NE, Zarate CA Jr "A Family History of Alcohol Dependence Alters Antidepressant Response to Oral Riluzole After Ketamine Infusion," Poster presented 16-18 May 2013 at the Society of Biological Psychiatry 68th Annual Meeting, San Francisco, CA, U.S.A.

6. Brockmeyer JS, Zarate CA Jr, Luckenbaugh DA, Rasimas JJ, Mathews DC, Ionescu DF, **Niciu MJ**, Richards EM, Furey ML "Anti-depressant Treatment History as a Predictor of Response to Scopolamine." Poster presented 16-18 May 2013 at the Society of Biological Psychiatry 68th Annual Meeting, San Francisco, CA, U.S.A.
7. Fujita M, Hines C, Zoghbi S, **Niciu M**, Ionescu D, Mallinger A, Zhang Y, Pike V, Drevets W, Innis R, Zarate CA "Changes in Brain Phosphodiesterase Type 4 Measured with 11C-(R)-Rolipram PET in Major Depressive Disorder." Poster presented 16-18 May 2013 at the Society of Biological Psychiatry 68th Annual Meeting, San Francisco, CA, U.S.A.
8. Innis RB, Fujita M, Ionescu D, **Niciu M,** Zohgbi S, Pike V, Drevets W and Zarate C "Binding of 11C-(R)-Rolipram to Phosphodiesterase 4 is Downregulated in Major Depressive Disorder and Normalized with Antidepressant Treatment." Poster presented 9-13 November 2013 at the Society for Neuroscience 43rd Annual Meeting, San Diego, CA, U.S.A.
9. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Nolan NM, Brutsche NE, Zarate CA Jr. "Clinical Predictors of Ketamine's Antidepressant Response in Treatment-Resistant Major Depression." Poster presented 21 Feb 2014 at the 16th Annual Fellows' Scientific Training Day, Emmitsburg, MD, U.S.A.
10. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Guevara S, Machado-Vieira R, Richards EM, Nolan NM, Brutsche NE, Zarate CA Jr. "Clinical Predictors of Ketamine's Antidepressant Response in Treatment-Resistant Major Depression." Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
11. Ionescu DF, Luckenbaugh DA, Slonena EE, **Niciu MJ**, Richards EM, Zarate CA Jr "A Comparison of Mood Improvements Following a Single Infusion of an N-methyl-D-aspartate (NMDA) Antagonist in Treatment-Resistant Patients with Anxious and Non-Anxious Depression." Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
12. Richards EM, Mathews DC, Machado-Vieira R, Luckenbaugh DA, **Niciu MJ**, Ionescu DF, Nolan N, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Smith MA, Cross A, Zarate CA Jr "A Randomized, Placebo-Controlled Pilot Trial of a Delta Opioid Agonist in Patients with Anxious Major Depression." Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
13. Lundin N, **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Richards EM, Zarate CA Jr "Do Vitamin B12 and Folate Predict Antidepressant Response to Ketamine in Major Depression?" Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
14. Iadorola N, Nugent AC, **Niciu MJ**, Salvadore G, Marquardt C, Holroyd T, Furey ML Zarate CA Jr "Differences During a Working Memory Task in Bipolar Depression as Detected by Magnetoencephalography" Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
15. Banerjee D, Nugent AC, Ionescu DF, **Niciu MJ**, Richards EM, Furey ML, Zarate CA "Altered White Matter Integrity May Predict Response to Ketamine in Major Depressive Disorder." Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
16. Fujita, M, Hines C, Ionescu DF, **Niciu MJ**, Richards EM, Zoghbi SS., Mallinger AG, Rallis-Frutos D, Xu R, Pike VW, Drevets W, Zarate CA, Innis RB "Cyclic AMP Cascade in Major Depressive Disorder Imaged with [11C]-(R)-Rolipram: Downregulation in Unmedicated Patients and Normalization by Antidepressant Treatment." Poster presented 8-10 May 2014 at the Society of Biological Psychiatry (SOBP) 69th Annual Meeting, New York, NY, U.S.A.
17. Fujita M, Hines C, Ionescu DF, **Niciu MJ**, Richards EM, Zoghbi SS, Mallinger AG, Rallis-Frutos D, Xu R, Pike VW, Drevets WC, Zarate CA Jr, Innis RB "Cyclic AMP Cascade in Major Depressive Disorder – Downregulation in Unmedicated Patients and Normalization by Antidepressant." Poster presented 21-24 May 2014 at the 10th International Symposium on Functional NeuroReceptor Mapping (NRM) of the Living Brain, The Netherlands.
18. **Niciu MJ**, Luckenbaugh DA, Ionescu DF, Nolan NM, Richards EM, Brutsche NE, Guevara S, Zarate CA Jr "Do the Dissociative Side Effects of Ketamine Mediate its Antidepressant Effects?"

Poster presented 16-19 June 2014 at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Hollywood, FL, U.S.A.

19. **Niciu MJ,** Luckenbaugh DA, Ionescu DF, Richards EM, Brutsche NE, Machado-Vieira R, Zarate CA Jr "Riluzole Likely Lacks Antidepressant Efficacy in Ketamine Non-Responders." Poster presented 7-11 December 2014 at the American College of Neuropsychopharmacology (ACNP) 53rd Annual Meeting in Phoenix, AZ, U.S.A.
20. **Niciu MJ,** Xu AX, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr "Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression." Poster presented 14-16 May 2015 at the Society of Biological Psychiatry (SOBP) 70th Annual Meeting, Toronto, ON, CA
21. **Niciu MJ,** Iadorola ND, Luckenbaugh DA, Banerjee D, Richards EM, Ballard ED, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA Jr "Ketamine's Antidepressant Efficacy is not Correlated with Baseline Subcortical Volumes in a Major Depressive Disorder Replication Sample." Poster presented 6-10 December 2015 at the American College of Neuropsychopharmacology (ACNP) 54th Annual Meeting in Hollywood, FL, U.S.A.
22. Richards EM, Zanotti-Fregonara P, Fuijita M, Walls T, **Niciu MJ**, Park M, Machado-Vieira R, Salvadore G, Kolb H, Zarate CA, Innis RB "Increased PET Radioligand Binding to Translocator Protein Suggests that Major Depressive Disorder is Associated with Neuroinflammation." Poster presented 6-10 December 2015 at the American College of Neuropsychopharmacology (ACNP) 54th Annual Meeting in Hollywood, FL, U.S.A.
23. **Niciu MJ,** Iadorola ND, Luckenbaugh DA, Banerjee D, Richards EM, Ballard ED, McMahon FJ, Machado-Vieira R, Nugent AC, Zarate CA Jr "Decreased Thalamic Volume Correlates with Increased Antidepressant Response to Ketamine in Brain-Derived Neurotrophic Factor (BDNF) rs6265 (val66met) Single Nucleotide Polymorphism Met Carriers." Poster presented 12-14 May 2016 at the Society of Biological Psychiatry (SOBP) 71st Annual Meeting in Atlanta, GA, U.S.A.
24. Park, M, Luckenbaugh DA, Newman LE, **Niciu MJ**, Lener MS, Machado-Vieira R, Zarate CA Jr. "Change in Cytokine Levels is not Associated with Antidepressant Response to Ketamine in Patients with Treatment Resistant Depression." Poster presented 12-14 May 2016 at the Society of Biological Psychiatry (SOBP) 71st Annual Meeting in Atlanta, GA, U.S.A.
25. Pennybaker SJ, **Niciu MJ**, Luckenbaugh DA, Zarate CA Jr. "Clinical Correlates of Ketamine's Antidepressant Efficacy in Extended Responders." Poster presented 12-14 May 2016 at the Society of Biological Psychiatry (SOBP) 71st Annual Meeting in Atlanta, GA, U.S.A.
26. Jaso BA, Luckenbaugh D, **Niciu MJ**, Zarate CA Jr. "Dissociative Symptoms in Patients with Bipolar Disorder in Response to Ketamine." Poster presented 12-14 May 2016 at the Society of Biological Psychiatry (SOBP) 71st Annual Meeting in Atlanta, GA, U.S.A.
27. Richards EM, Fregonara PZ, Fujita M, Newman L, **Niciu M**, Park M, Machado-Vieira R, Salvadore G, Kolb H, Zarate CA Jr. "Using PET Imaging of Translocator Protein (TSPO) to Investigate the Link Between Inflammation and Depression." Poster presented 12-14 May 2016 at the Society of Biological Psychiatry (SOBP) 71st Annual Meeting in Atlanta, GA, U.S.A.
28. Yazdian AL, Park L, Luckenbaugh DA, **Niciu MJ**, Lener M, Nugent AC, Ballard ED, Brutsche NE, Zarate CA Jr. "Clinical Predictors of Placebo Response in Treatment-Resistant Major Depression." Poster presented 12-14 May 2016 at the Society of Biological Psychiatry (SOBP) 71st Annual Meeting in Atlanta, GA, U.S.A.
29. **Niciu MJ**, Pennybaker SJ, Luckenbaugh DA, Zarate CA Jr. "Symptomatology and Predictors of Ketamine's Antidepressant Efficacy in Extended Responders." Poster presented 29 September 2016 at the 18th Annual NIMH DIRP Fellows' Scientific Training Day, Leesburg, VA, U.S.A.
30. Averill LA, Abdallah CG, **Niciu MJ**, Fenton LR, Fasula MK, Jiang L, Rothman DL, Mason GF, Sanacora G "Early Life Stress and Glutamate Neurotransmission in MDD" Poster presented 4-8 December 2016 at the American College of Neuropsychopharmacology (ACNP) 55th Annual Meeting in Hollywood, FL, U.S.A.
31. Ballard E, Vande Voort J, Luckenbaugh DA, Bernert RA, Richards EM, **Niciu MJ**, Park L, Machado-Vieira, Duncan WC Jr., Zarate CA Jr. "Nocturnal Wakefulness as a Clinical Correlate of Next-Day Suicidal Thoughts and Antisuicidal Response to Ketamine in Depressed Patients"

Poster presented 4-8 December 2016 at the American College of Neuropsychopharmacology (ACNP) 55th Annual Meeting in Hollywood, FL, U.S.A.

32. Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, **Niciu MJ**, Machado-Vieira R, Salvadore G, Kolb H, Drevets WC, Zarate CA Jr., Innis RB "PET Imaging of the Translocator Protein (TSPO): Investigating the Link Between Inflammation and Depression" Poster presented 4-8 December 2016 at the American College of Neuropsychopharmacology (ACNP) 55th Annual Meeting in Hollywood, FL, U.S.A.
33. **Niciu MJ**, Pennybaker SJ, Luckenbaugh DA, Zarate CA Jr. "Symptomatology and Predictors of Ketamine's Antidepressant Efficacy in Extended Responders." Poster presented 4-8 December 2016 at the American College of Neuropsychopharmacology (ACNP) 55th Annual Meeting in Hollywood, FL, U.S.A.
34. Shovestul B, Jaso B, Luckenbaugh D, Park L, **Niciu M**, Zarate C Jr. "Association between Specific Dissociative Symptoms and Symptom Subsets and Anti-Depressant Response to Ketamine" Poster presented 18-20 May 2017 at the Society of Biological Psychiatry (SOBP) 72nd Annual Meeting in San Diego, CA, U.S.A.
35. Richards E, Zanotti-Fregonara P, Newman L, Fujita M, **Niciu M**, Machado-Vieira R, Salvadore G, Kolb H, Drevets W, Innis R, Zarate C, Jr. "Correlating Peripheral and Central Markers of Neuroinflammation to PET Imaging of Translocator Protein (TSPO)" Poster presented 18-20 May 2017 at the Society of Biological Psychiatry (SOBP) 72nd Annual Meeting in San Diego, CA, U.S.A.
36. Ballard E, Luckenbaugh D, Yarrington J, Lally N, Lener M, Machado-Vieira R, Kadriu B, **Niciu M**, Park L, Zarate C "A Principal Components Analysis of Depression and Anhedonia Scales: Illustrating the Heterogeneity of Depression" Poster presented 18-20 May 2017 at the Society of Biological Psychiatry (SOBP) 72nd Annual Meeting in San Diego, CA, U.S.A.
37. Kadriu B, Gold P, Lener M, Ballard E, **Niciu M**, Yuan P, Luckenbaugh D, Machado-Vieira R, Zarate C "Acute Ketamine Administration Corrects Abnormal Inflammatory Bone Markers in Major Depression" Poster presented 18-20 May 2017 at the Society of Biological Psychiatry (SOBP) 72nd Annual Meeting in San Diego, CA, U.S.A.
38. Yarrington J, Ballard E, Luckenbaugh D, **Niciu M**, Lener M, Kadriu B, Park L, Zarate C "Clinical Predictors of an Antisuicidal Response to Ketamine" Poster presented 18-20 May 2017 at the Society of Biological Psychiatry (SOBP) 72nd Annual Meeting in San Diego, CA, U.S.A.
39. **Niciu MJ**, Shovestul BJ, Jaso BA, Farmer, C, Luckenbaugh DA, Park LT, Ballard ED, Zarate CA Jr. "Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Major Depression." Poster presented 11 September 2017 at the 19th Annual NIMH DIRP Fellows' Scientific Training Day, Leesburg, VA, U.S.A.
40. **Niciu MJ**, Shovestul BJ, Jaso BA, Farmer, C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard ED, Zarate CA Jr. "Features of Dissociation Differentially Predict Antidepressant Response to Ketamine in Treatment-Resistant Major Depression." Poster presented 3-7 December 2017 at the American College of Neuropsychopharmacology (ACNP) 56th Annual Meeting in Palm Springs, CA, U.S.A.
41. **Niciu MJ**, Jaso BA, Shovestul BJ, Ramchandani V, Zarate CA Jr. "The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Antidepressant Effects," Poster presented 19-21 February 2019 at the International Society of CNS Clinical Trials and Methodology (ISCTM) 15th Annual Meeting in Washington, DC, U.S.A.
42. Ramchandran K, Phadke S, Mott, **Niciu M**, Magnotta V, Trapp N "Repetitive Intermittent Accelerated Transcranial magnetic stimulation (iTBS) as a potential intervention for chemotherapy induced cognitive deficits (CICD) – a pilot clinical trial to explore feasibility and efficacy." Poster presented (virtually) 21 October 2020 at the University of Iowa Health Care's Internal Medicine Research Day in Iowa City, IA, U.S.A.
43. Decker AC, Bacalzo B, Randall ZM, **Niciu MJ** "Bioenergetic Effects of Ketamine and its Bioactive Metabolites in Human Cells." Poster presented 6-9 December 2020 at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting (virtual meeting)

44. **Niciu MJ**, Kinnaird B, Lee K-P "Neuronal Monoaminergic Antidepressant Response Signatures in the L1000 Database." Poster presented 5-8 December 2021 at the American College of Neuropsychopharmacology (ACNP) 60th Annual Meeting in San Juan, Puerto Rico
45. Schmidt N, Guiler W, Decker A, Kinnaird B, Schuebel K, Zarate CA, Goldman D, **Niciu MJ** "Whole and Single Cell Human Cortical Spheroid Transcriptomics in Response to Low-Dose Ketamine." Poster presented 4-7 December 2022 at the American College of Neuropsychopharmacology (ACNP) 61st Annual Meeting in Phoenix, AZ, U.S.A.

Seminars – Other:

1. **Niciu MJ** "Subtypes of Major Depression in Substance Dependence," University of Connecticut School of Medicine Scholars in Medicine Banquet Dinner, Invited Speaker, May 2008, Avon, CT, U.S.A.
2. **Niciu MJ** " Rapid and Sustained Antidepressant Effects of Ketamine: Therapeutic Implications." George Washington University Department of Psychiatry Grand Rounds: 24 October 2013, Washington, DC, U.S.A.
3. **Niciu MJ** " Rapid and Sustained Antidepressant Effects of Ketamine: Therapeutic Implications." National Institutes of Health (NIH)/National Institute on Alcoholism and Alcohol Abuse (NIAAA) Laboratory of Clinical and Translational Studies (LCTS) Seminar Series: 25 November 2013, National Institutes of Health/National Institutes of Mental Health (NIH/NIAAA) Bethesda, MD, U.S.A.
4. **Niciu MJ** "Rapid and Sustained Antidepressant Effects of Ketamine: Therapeutic Implications." Fellows Afternoon Neuroscience Seminar (FANS): 19 December 2013, National Institutes of Health/National Institutes of Mental Health (NIH/NIMH) Bethesda, MD, U.S.A.
5. **Niciu MJ** "Ketamine's Antidepressant Efficacy is not Correlated with Baseline Subcortical Volumes in a Major Depressive Disorder Replication Sample," 25 September 2015, 17th Annual NIMH DIRP Fellows' Scientific Training Day, Leesburg, VA, U.S.A. (selected)
6. **Niciu MJ** "Ketamine and Familial Risk for Alcoholism: Strange Bedfellows in TRD Tx?" 5 October 2015, NIMH Outstanding Resident Award Training Program (ORAP), Bethesda, MD, U.S.A.
7. **Niciu MJ** "Ketamine and Familial Risk for Alcoholism: Strange Bedfellows in TRD Tx?" 8 March 2016, Icahn/Mt. Sinai School of Medicine Mood and Anxiety Disorders Program (MAP) Seminar, New York, NY, U.S.A.
8. **Niciu MJ** "Ketamine and Familial Risk for Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression." 11 October 2016, NIMH Investigator's Seminar Series, "Biomarkers and Brain Disease: How can they help with diagnosis and treatment?" Bethesda, MD, U.S.A.
9. **Niciu MJ,** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 28 February 2017, University of Minnesota School of Medicine Psychiatry Colloquium, Minneapolis, MN, U.S.A.
10. **Niciu, MJ** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 6 March 2017, NIAAA Clinical Seminar, Bethesda, MD, U.S.A.
11. **Niciu MJ,** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 21 March 2017, USC/Keck School of Medicine Psychiatry Grand Rounds, Los Angeles, CA, U.S.A.
12. **Niciu MJ,** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 29 March 2017, University of Iowa/Carver School of Medicine Psychiatry Colloquium, Iowa City, IA, U.S.A.
13. **Niciu MJ,** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 17 April 2017, Vanderbilt University School of Medicine Psychiatry Seminar, Nashville, TN, U.S.A.
14. **Niciu MJ,** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 2 May 2017, University of Connecticut Health Center Department of Neuroscience Seminar, Farmington, CT, U.S.A.

15. **Niciu MJ,** "Ketamine and Family History of Alcohol Use Disorders: Strange Bedfellows in the Treatment of Resistant Depression?" 24 May 2018, Psychiatry Research Faculty Luncheon, Iowa City, IA, U.S.A.
16. **Niciu MJ**, "Ketamine in Treatment-Resistant Depression," 29 January 2019, University of Iowa Health Care Psychiatry Grand Rounds, Iowa City, IA, U.S.A.
17. **Niciu MJ**, "Ketamine in Treatment-Resistant Depression," 13 February 2019, University of Nebraska Health Care Psychiatry Grand Rounds, Omaha, NE, U.S.A.
18. **Niciu MJ,** "Ketamine in Treatment-Resistant Depression," 28 January 2020, University of Iowa Health Care Neurology Grand Rounds, Iowa City, IA, U.S.A.
19. **Niciu, MJ,** "The Interventional Psychiatry Service Patient Registry," 17 November 2020, University of Iowa Health Care Psychiatry Grand Rounds, Virtual (Iowa City, IA U.S.A.)
20. **Niciu MJ,** ROUNDING@IOWA [CME (0.75 credit hours) Podcast: 8. The Hopes and Complexities of Ketamine for Treatment Refractory Depression (https://uiowace.libsyn.com/8-the-hopes-and-complexities-of-ketamine-for-treatment-refractory-depression), 1 February 2021, Iowa City, IA, U.S.A.
21. **Niciu, MJ** "Transcriptional Antidepressant Response Signatures: A Collaboration with the Iowa Initiative for Artificial Intelligence," University of Iowa Health Care Psychiatry Grand Rounds, 22 February 2022, Virtual (Iowa City, IA, U.S.A.)
22. **Niciu MJ,** "Es/ketamine in Treatment-Resistant Depression," National Alliance of Mental Illness (NAMI) Johnson County "Lunch-and-Learn," 18 January 2023, Virtual (Iowa City, IA, U.S.A.)
23. **Niciu MJ** "Es/ketamine in Treatment-Resistant Depression," University of Connecticut Family Medicine/Trinity Health of New England Family Medicine Grand Rounds," 29 March 2023, Virtual (Hartford, CT, U.S.A.)
24. **Niciu MJ** "Es/ketamine in Treatment-Resistant Depression," 2023 PROGRESS Conference, 06 October 2023, Coralville, IA, U.S.A.
25. **Niciu MJ** "Es/ketamine in Treatment-Resistant Depression," 2023 UTHealth Houston Mood Disorders Conference, 14 October 2023, Houston, TX, U.S.A.
26. **Niciu MJ** "Portrait of the Physician-Scientist as a Middle-Aged Man," University of Connecticut Psychiatry Interest Group, 01 February 2024, Virtual (Farmington, CT, U.S.A.)
27. **Niciu MJ** "Es/ketamine in Treatment-Resistant Depression," University of Connecticut Department of Psychiatry Grand Rounds, 02 February 2024, Virtual (Farmington, CT, U.S.A.)
28. **Niciu MJ**, Maurer C, "Psilocybin-Assisted vs. Ketamine-Assisted Psychotherapy for Alcohol Use Disorder," University of Iowa Department of Psychiatry Grand Rounds, 13 February 2024
29. **Niciu MJ** "My Clinical and Research Experience with Ketamine/Psychedelics," University of Iowa/Carver College of Medicine Psychiatry Interest Group, 28 March 2024

Grants:

- NARSAD/Brain and Behavior Research Foundation (BBRF) Young Investigator Award, "A Cellular and Molecular Investigation of Ketamine's Enhanced Antidepressant Efficacy in Subjects with a Family History of an Alcohol Use Disorder," Award Period: 01/2016-12/2017
- NIH Pathway to Independence Award (1 K99 AA024142-01) "A Neurobiological Investigation of Ketamine's Enhanced Antidepressant Efficacy in Subjects with a Family History of an Alcohol Use Disorder." K99R00 Award Period: 01/2016-08/2023

Awards/Distinctions:

- Manhattan College Dean's List - All Semesters from Fall 1995-Spring 1999
- Beta Beta Beta Biological Honors Society - Inducted May 1998
- Phi Beta Kappa Humanities Honor Society - Inducted May 1998
- Manhattan College Class of 1999 - Summa Cum Laude
- Manhattan College Class of 1999 - Biology Department First in Class
- Manhattan College Class of 1999 - General Excellence Award in Science and Mathematics
- National Institutes of Health (NIH) Medical Scientist Training Program (M.D./Ph.D.) Trainee, University of Connecticut Health Center - July 2000-May 2008

• Trainee Travel Award, American Society of Clinical Investigation (ASCI)/Association of American Physicians (AAP) Joint Meeting – selected for travel award to attend the annual conference and present research-in-progress via poster from 25-27 April 2003 in Chicago, IL, U.S.A.
• Young Investigator Educational Enhancement Travel Award, American Society of Neurochemistry – selected for travel award to attend the annual conference and present research-in-progress via seminar from 11-15 March 2006 in Portland, OR, U.S.A.
• National Institutes of Health (NIH)/National Institute of Mental Health (NIMH) Outstanding Resident Award Program (awarded in 2010 to ~12 PGY-2 psychiatry residents in the U.S. for their outstanding clinical and research accomplishments and potential for future distinction in the field)
• Yale University Department of Psychiatry McNeil Fellowship in Translational Neuropsychopharmacology Research - 2010-1 Academic Year
• National Institutes of Health (NIH)/National Institute of Mental Health (NIMH)-Sponsored Brain Camp 2011 Attendee – selected to attend National Institutes of Health (NIH)/National Institutes of Mental Health (NIMH)-sponsored symposium at Cold Springs Harbor Laboratories in Huntington, NY, U.S.A.
• American Society of Clinical Psychopharmacology (ASCP) 2012 Workshop on Clinical Trials in Psychopharmacology Fellowship Award Recipient – selected for travel award to attend workshop from Tues., 24 April – Thurs. 26 April 2012 in New York, NY, U.S.A.
• American Psychiatric Association (APA) Research Colloquium for Junior Investigators - selected for travel award to present research-in-progress via seminar and poster on Sun., 6 May 2012 in Philadelphia, PA, U.S.A.
• Laughlin Award for Merit, Yale University Department of Psychiatry, New Haven, CT, U.S.A. – 2011-2 Academic Year
• Class of 2013 CDI Bipolar Disorder Award Recipient – selected for travel award to attend career development symposium and research-in-progress via seminar from Sat., 6 April – Tues., 10 April 2013 in Pittsburgh, PA, U.S.A.
• NIMH Seymour Kety Memorial Fellowship Training Award for Clinical Research – awarded on Fri., 21 February 2014
• 2014 American Society of Clinical Psychopharmacology (ASCP) New Investigator Award (NIA) – selected for travel award to attend career development seminar on Sun., 15 June 2014 and annual meeting from Mon., 16 June – Thurs. 19 June 2014 in Hollywood, FL, U.S.A.
• 2015 NARSAD/Brain and Behavior Research Foundation (BBRF) Young Investigator Award
• 2016 Society of Biological Psychiatry (SOBP) Early Career Investigator (Domestic) Travel Award – selected for travel award to attend the Society of Biological Psychiatry (SOBP)'s 71st Annual Meeting from 12-14 May 2016 in Atlanta, GA, U.S.A.
• 2016 American College of Neuropsychopharmacology (ACNP) Travel Award – selected for travel award to attend the American College of Neuropsychopharmacology (ACNP)'s 55th Annual Meeting from 4-8 December 2016 in Hollywood, FL, U.S.A.
• 2019 International Society of CNS Clinical Trials and Methodology (ISCTM) New Investigator Award – selected for travel award to attend the International Society of CNS Clinical Trials and Methodology (ISCTM) Winter Meeting from 19-21 February 2019 in Washington, DC, U.S.A.
• 2019 University of Iowa Computational Psychiatry/Iowa Initiative for Artificial Intelligence IAII)Pilot Award, "Antidepressant Signatures based on Single Cell Transcriptomics (sc-RNA-Seq) in Human Induced Pluripotent Stem Cell (hiPSC)-derived Human Cortical Spheroids (hCSs) - ~$10,000 research/personnel support to assist with project x 1 year

Academic Service:

• Yale University Department of Psychiatry PGY-1,2 Graduate Education Committee Representative - 2009-10 Academic Year

• Yale University Department of Psychiatry PGY-3 Graduate Education Committee Representative - 2010-11 Academic Year
• Program-Wide Chief Resident, Yale University Department of Psychiatry, New Haven, CT - 2011-2 Academic Year
• Chief Resident, Connecticut Mental Health Center's (CMHC) Clinical Neuroscience Research Unit (CNRU), Yale University Department of Psychiatry, New Haven, CT - 2011-2 Academic Year
• NIMH Fellows Committee Representative, Bethesda, MD – 2012-3 Academic Year
• NIMH Fellows Committee Representative, Bethesda, MD – 2013-4 Academic Year
• NIMH Fellows Committee Representative, Bethesda, MD – 2014-5 Academic Year
• NIMH Fellows Committee Representative, Bethesda, MD – 2015-6 Academic Year
• NIMH-DIRP 16th Annual Fellows' Scientific Training Day (FEMA Training Center, Emmitsburg, MD; 21 February 2014) Planning Committee, Bethesda, MD – 2014-5 Academic Year
• NIMH-DIRP 17th Annual Fellows' Scientific Training Day (National Conference Center, Leesburg, VA; 25 September 2015) Planning Committee, Bethesda, MD – 2015-6 Academic Year
• NIMH-DIRP 18th Annual Fellows' Scientific Training Day (National Conference Center, Leesburg, VA; 29 September 2016) Planning Committee, Bethesda, MD – 2016-7 Academic Year
• Washington Psychiatric Society (D.C.-based branch of the American Psychiatric Association), Early Career Psychiatrist Representative (elected, 1st term) – 2012-3 Academic Year
• Washington Psychiatric Society (D.C.-based branch of the American Psychiatric Association), Early Career Psychiatrist Representative (elected, 1st term) – 2013-4 Academic Year
• Washington Psychiatric Society (D.C.-based branch of the American Psychiatric Association), Early Career Psychiatrist Representative (elected, 2nd term) – 2014-5 Academic Year
• Washington Psychiatric Society (D.C.-based branch of the American Psychiatric Association), Early Career Psychiatrist Representative (elected, 2nd term) – 2015-6 Academic Year
• National Neuroscience Curriculum Initiative (NNCI), editorial board, "Translational Neuroscience" module – 2015-6 Academic Year
• Symposium Co-Chair (with Chair: James Murrough M.D.) "Advancing Human Biomarker Discovery in Severe and Treatment-Resistant Depressive Disorders" – American College of Neuropsychopharmacology (ACNP) 2016 55th Annual Meeting, 4-8 December 2016 in Hollywood, FL, U.S.A.
• Symposium Chair (with Co-Chair Dawn F. Ionescu M.D.) "Novel Biomarkers of Ketamine's Response in Depression, Anxiety and Suicide" – Anxiety and Depression Association of America (ADAA)'s Anxiety and Depression Conference 2017, 6-9 April 2017 in San Francisco, CA, U.S.A.
• Mentor at the American College of Neuropsychopharmacology (ACNP) 56th Annual Meeting, 3-7 December 2017 in Palm Springs, CA, U.S.A.
• Mentor at the American College of Neuropsychopharmacology (ACNP) 57th Annual Meeting, 9-13 December 2018 in Hollywood, FL, U.S.A.
• Mentor at the Society of Biological Psychiatry (SOBP) 74th Annual Meeting, 16-18 May 2019 in Chicago, IL, U.S.A.
• Mentor at the American College of Neuropsychopharmacology (ACNP) 58th Annual Meeting, 8-11 December 2019 in Orlando, FL, U.S.A.
• Discussant ("Publications") for the ACNP Travel Awardee Roundtable Breakfast at the American College of Neuropsychopharmacology (ACNP) 58th Annual Meeting, 8-11 December 2019 in Orlando, FL, U.S.A.
• National Network of Depression Centers (NNDC) Ketamine Task Force Co-Chair – 11/2019-present
• Mentor at the American College of Neuropsychopharmacology (ACNP) 59th Annual Meeting, 6-9 December 2020 (virtual meeting)

• Mentor at the American College of Neuropsychopharmacology (ACNP) 60th Annual Meeting, 5-8 December 2021 in San Juan, Puerto Rico
• Discussant ("M.D. Ph.D. Trainee Roundtable Discussions") for the ACNP Travel Awardee Roundtable Breakfast at the American College of Neuropsychopharmacology (ACNP) 60th Annual Meeting, 5-8 December 2021 in San Juan, Puerto Rico

• University of Iowa Health Care/Carver College of Medicine Mood Disorders Center Interviewer – 2018-9 Academic Year, 2019-20 Academic Year
• University of Iowa Health Care/Carver College of Medicine Mood Disorders Case Conference Interviewer – 2018-9 Academic Year, 2019-20 Academic Year
• University of Iowa Health Care/Carver College of Medicine Psychiatry Residency Applicant Interviewer – 2018-9 Academic Year, 2019-20 Academic Year
• University of Iowa Health Care/Carver College of Medicine Interdisciplinary Graduate Program in Neuroscience Awards Committee – 2021-2 Academic Year, 2022-3 Academic Year

• University of Iowa Health Care Interventional Psychiatry Service (IPS) – psychiatrist lead on the establishment of both intravenous ketamine and intranasal esketamine (Spravato™) for treatment-refractory depression
• Completion of 8 hours of evidence-based research mentor training at the University of Iowa. Curriculum Reference: Pfund, C., Handelsman, J., & Branchaw, J. (2014). Entering mentoring. WH Freeman.
• Completion of 6 hours of Culturally-Aware Mentoring (CAM) Training at the University of Iowa (Thurs., 24 March and Thurs., 31 March 20222 2-5 P.M. CST) as sponsored by the CAM Study team at University of Madison-Wisconsin (a member of the NIH-funded Diversity Program Consortium)

• Ad Hoc *Peer Reviewer:*
Alcohol
Biological Psychiatry (Biol Psychiatry)
BMJ Case Reports (BMJ Case Rep)
Current Neuropharmacology (Curr Neuropharmacol)
Clinical Psychology (Clin Psychol)
CNS Spectrums
Current Psychiatry
Drugs in Context (Drugs Context)
Environmental Toxicology and Pharmacology (Environ Toxicol Pharmacol)
Genes, Brain and Behavior (Genes Brain Behav)
The International Journal of Neuropsychopharmacol (Int J Neuropsychopharmacol)
Journal of Affective Disorders (J Affect Disord)
Journal on Studies of Alcohol and Drugs (J Stud Alc Drugs)
Journal of Clinical Psychiatry (J Clin Psychiatry)
Journal of Clinical Psychopharmacology (J Clin Psychopharmacol)
The Journal of Nervous and Mental Disease (J Nerv Ment Dis)
Journal of Psychopharmacology (J Psychopharmacol)
Journal of Psychoactive Drugs (J Psychoactive Drugs)
Journal of Psychiatric Research (J Psych Res)
Molecular Psychiatry (Mol Psychiatry)
Neuropsychopharmacology
Progress in Neuro-Psychopharmacology & Biol Psychiatry (Prog Neuropsychopharmacol Biol Psychiatry)
Psychiatric Research (Psychiatr Res)
Therapeutic Advances in Psychopharmacology (Ther Adv Psychopharmacol)
Translational Psychiatry (Transl Psychiatry)

The World Journal of Biological Psychiatry (World J Biol Psychiatry)

Professional Associations:

- American Psychiatric Association (APA) – Member (2008-present), Fellow (2013-present)
- Society of Biological Psychiatry (SOBP) – Member (2013-present)
- American College of Neuropsychopharmacology (ACNP) – Associate Member (2017-present)

Teaching:

- Yale University Department of Psychiatry Medical Student Clerkship Interview and Write-Up Tutor – 2009-12 Academic Years (PGY-2-through-4)
- Yale University Department of Psychiatry Centralized Curriculum (PGY-2) – 2011-2 Academic Year:
  - American Psychiatric Association (APA) Clinical Guidelines for Treatment of Major Depressive Disorder
  - Neurobiology of Borderline Personality Disorder
- NIMH Post-Bac IRTA Brown Bag Series: Clinical Careers, "M.D. vs. M.D.-Ph.D." 25 September 2014 (panel series)
- National Neuroscience Curriculum Initiative (NNCI), "Translational Neuroscience (Experimental Therapeutics – Ketamine, Scopolamine and Infliximab – for Major Depression) – 2014-5 Academic Year (3rd Year Clinical Fellow)
- NIMH Summer Journal Club, "Ketamine and Depression," 21 July 2015 (1.5 hour session for NIMH Summer students – mostly high school and college)
- FAES/NIMH Current Trends in the Neurobiology of Mental Illness Course, "Stem Cell Technologies in Neuropsychiatric Disorders," 24 November 2015 (~1 hour lecture and Q&A with post-baccalaureate fellows, postdoctoral fellows, clinical fellows, *etc*.)
- FAES/NIAAA The Neurobiology of Addiction Course, "Ketamine & Familial Risk for Alcohol Use Disorders: Strange Bedfellows in Tx of TRD," 28 April 2016 (~1 hour lecture and Q&A with post-baccalaureate fellows, postdoctoral fellows, clinical fellows, *etc*.)
- University of Iowa Health Care/Carver College of Medicine Psychiatry Residency PGY-3/4 Lectures:
  - "Psychiatric Epidemiology," 08/14/2018 08:00-45
  - "Epidemiology of Alcohol and Drug Abuse and Dependence," 08/28/2018 08:00-45
- University of Iowa Health Care/Carver College of Medicine Psychiatry Residency Journal Club (with Dr. Holly Van Den Belt), "Williams et al. (2018) Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. *Am J Psychiatry* **175**(12):1205-15, PMID: 30153752; 10/31/2018 12:00-13:00
- University of Iowa Health Care/Carve College of Medicine Psychiatry Residency Evidence-Based Medicine (EBM) Mini-Lectures:
  - "Type II Error" 11/05/2019 12:00-15;
  - "Study Design: Sample Size Calculator and Power" 11/12/2019 12:00-15
  - "Intention-to-Treat Analysis," 03/16/2020 12:00-15

Mentoring:

Alexandra Alario B.S., Ph.D.: Alex was a graduate student in the University of Iowa's Interdisciplinary Graduate Program in Neuroscience. She joined the laboratory in 2020, and, based on her thesis project on biomarkers in transcranial magnetic stimulation (TMS), decided to be co-mentored by Nicholas Trapp M.D. She spearheaded projects investigating cardiovascular- and electroencephalography (EEG)-based biomarkers of antidepressant response to TMS in treatment-resistant major depressive disorder and bipolar disorder. More specifically, she investigated heart rate decelerations/variability and visual evoked potentials (long-term potentiation) via electrocardiogram (EKG) and EEG, respectively. Alex is currently a postdoctoral fellow at Yale (New Haven, CT) in Sarah Fineberg M.D. Ph.D.'s laboratory.

Nicholas Berray B.A.: Nick was a volunteer high school student in our group in the Summer of 2014. He provided technical assistance in the harvesting and processing of peripheral blood mononuclear cells (PBMCs) from currently-depressed patients with major mood disorders (including major depressive disorder and bipolar depression) and healthy volunteers. Nick completed undergraduate at Duke University, graduating cum laude in Multidisciplinary Studies. He is currently working at a Content Producer at Narrative in Los Angeles, CA.

Sage Comstock M.A.: Sage is a research assistant who commenced work in the Niciu laboratory in September 2018 after completing a Master's Degree in Clinical Psychology from the University of Northern Iowa (UNI). She has assisted with ongoing clinical research activities, particularly the Ketamine Alcohol protocol's transition from the National Institutes of Health (NIH)/National Institute of Mental Health (NIMH) to the University of Iowa. She completed a first-author review article in *Chronic Stress (Thousand Oaks)* on the differential drug response and neurobiological differences in subjects with a first-degree relative with an alcohol use disorder. She left the laboratory in August 2021 to pursue a nursing degree at Kirkwood Community College. She is currently a licensed practicing nurse (LPN) studying to become a registered nurse (RN).

Amanda Decker Ph.D.: Amanda is a postdoctoral fellow who joined the Niciu laboratory in November 2018. She is broadly interested in cell fate decision-making in the central nervous system and using stem cell-based three-dimensional organoid cultures to investigate neurodevelopmental processes. She has commenced work on glutamatergic mechanism(s) of disease and antidepressant response to subanesthetic dose ketamine and its bioactive metabolites using a human transformed cell line (SK-N-SH) and hiPSC-derived hCSs. She is also interested in the role of the opioid system in neurodevelopment and its relation to neonatal abstinence syndrome (NAS). She received internal funding (Pappajohn Biomedical Institute Microfinance Grant) in 07/2019 to investigate opioid receptor expression in developing spheroids. She left the laboratory in February 2021. She is currently working as a Biomedical Editor at General Dynamics Information Technology.

Nicolas Iadarola M.D.: Nico was a post-baccalaureate research associate who worked in the Experimental Therapeutics and Pathophysiology Branch in the 2013-5 academic calendar years. I mentored Nico on researching and writing the following review article: Iadarola *et al.* (2015) *Ther Adv Chron Dis.* Nico completed Georgetown University's Post-baccalaureate Pre-Medical Certification Program in 2016. He completed medical school at the University of Arizona College of Medicine – Tucson and is now a psychiatry resident at the University of Maryland.

Brittany Jaso Ph.D.: Brittany was a post-baccalaureate research associate who worked in the Experimental Therapeutics and Pathophysiology Branch in the 2014-6 academic calendar years. As the lead research associate for the ketamine alcohol protocol (14-M-0085, ClinicalTrials.gov identifier NCT02122562: "The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder"), I supervised Brittany as the primary research assistant on this project. I also supervised Brittany as the lead author on an invited article on glutamatergic modulators as putative therapeutic options in major mood disorders. Brittany completed a Ph.D. in Clinical Psychology at the University of Miami. She worked as a postdoctoral fellow at Boston University's Center for Anxiety and Related Disorders (CARD).

Nancy Lundin Ph.D.: Nancy was a post-baccalaureate research associate who worked in the Experimental Therapeutics and Pathophysiology Branch in the 2013-5 academic calendar years. I mentored Nancy in a secondary data analysis of our exisiting ketamine database that resulted in the following article: Lundin et al. (2014) *Pharmacopsychiatry* **47**(4-5):141-4, PMID: 24955551. She completed her Ph.D. in the. Departments of Psychology and Neuroscience at the University of Indiana-Bloomington. She is currently a clinical psychology intern at Ohio State University.

Alejandro Merulo M.D. Ph.D.: Alejandro is currently an Assistant Professor in the Department of Psychiatry at the University of California – San Diego. I was his assigned mentor for the American

College of Neuropsychopharmacology (ACNP) 58th Annual Meeting, 8-11 December 2019 in Orlando, FL, U.S.A.

Steven Pennybaker M.D.: Steven was a Johns Hopkins Medical Student who was accepted and matriculated into the NIH's Medical Research Scholars Program (MSRP) for the 2015-6 academic calendar. Under the supervision of Dr. Zarate, I served as Steven's primary mentor. During this experience, I met with Steven for weekly individual and *ad hoc* supervision. Among other projects, Steven has investigated the demographic and clinical features of treatment-resistant depressed subjects who have extended/protracted antidepressant response to ketamine. He completed his psychiatry residency at the University of California San Francisco (UCSF) and is currently a staff psychiatrist at the Bay Psychiatric Associates.

Zoe Randall B.A.: Zoe is an undergraduate at Cornell College. She performed a 6-week Summer rotation in the laboratory from 05-07/2019. She worked on cell culture experiments with SK-N-SH cells with a postdoctoral fellow in my laboratory, Dr. Amanda Decker. She worked as a part time in the laboratory in 2020 before leaving for Uzbekistan for a Fulbright English Teaching Assistant (ETA) fellowship. Zoe is currently a medical school at the University of Minnesota (Minneapolis).

Courtney Rasimas (Sinclair) M.P.H..: Courtney was a post-baccalaureate research associate who worked in the Experimental Therapeutics and Pathophysiology Branch in the 2012-3 academic calendar years. I mentored her as she assisted me with the following book chapter: Niciu et al. (2014) Treatment of Depressive Disorders" in *Gabbard's Treatments of Psychiatric Disorders*, 5th edition, Arlington (VA): American Psychiatric Publishing, 2014, pp. 275-301. Courtney completed a M.P.H. at the University of Minnesota.

Ana Maria Rivas-Grajeles M.D.: Ana Maria completed her psychiatry residency at Baylor College of Medicine and is currently a Clinical Fellow in Psychiatry at Massachusetts General Hospital. Dr. Grajeles was my mentee for the American College of Neuropsychopharmacology (ACNP) 57th Annual Meeting, 9-13 December 2018 in Hollywood, FL, U.S.A.

Benjamin Samuels Ph.D.: Benjamin is an Assistant Professor in the Department of Psychology at Rutgers University. Dr. Samuels was my mentee for the American College of Neuropsychopharmacology (ACNP) 56th Annual Meeting, 3-7 December 2017 in Palm Springs, CA, U.S.A.

Natalia Schmidt M.D.: Natalia is a post-baccalaureate research associate who started working in the Experimental Therapeutics and Pathophysiology Branch in 09/2015 for two academic calendar years (2015-7). She functioned as the primary research assistant on stem cell experimentation from major depression subjects and healthy volunteers enrolled in ketamine infusion protocols. She completed medical school at the University of Virginia and is currently an internal medicine resident at Mt. Sinai/Icahn School of Medicine.

Bridget Shovestul B.A.: Bridget is a post-baccalaureate research associate who started working in the Experimental Therapeutics and Pathophysiology Branch 07/2016 for two academic calendar years. As the lead research associate for the ketamine alcohol protocol (14-M-0085, ClinicalTrials.gov identifier NCT02122562: "The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder"), I supervised Bridget as the primary research assistant on this project. She is currently a graduate student in a clinical psychology Ph.D. program at the University of Rochester.

Mary Vance (Zeng) M.D.: As a fourth-year medical student at SUNY-Downstate (Brooklyn), Mary performed a one-month clinical research rotation in the Experimental Therapeutics and Pathophysiology Branch in September 2012. During this time, I mentored Mary in a secondary data analysis of our existing ketamine database that resulted in the following publication: Zeng *et al.* (2014)

Biol Psychiatry **73**(12):e37-8; PMID: 23245747. Mary completed her adult psychiatry residency and clinical fellowship at Harvard-Massachusetts General Hospital.

Benjamin Wade Ph.D.: Benjamin was a postdoctoral fellow in the Ahamson-Lovelace Bran Mapping Center at the University of California, Los Angeles and Traumatic Brain Injury (TBI) and Concussion Center at the University of Utah. Benjamin was my mentee for the Society of Biological Psychiatry 74th Annual Meeting, 16-18 May 2019 in Chicago, IL, U.S.A.

Annie Xu M.D.: As a fourth-year medical student at New York Medical College, Annie performed a 2-month clinical research rotation in the NIMH Experimental Therapeutics and Pathophysiology Branch in July and August 2014. During this time, I mentored Annie in a secondary data analysis of our existing ketamine database that resulted in the following article: Xu *et al.* (2015) *Neural Plast* **2015**:858251, PMID: 26137324. Annie completed her adult psychiatry residency at New York Medical College. She then completed a psychosomatic medicine/psycho-oncology fellowship at Memorial Sloane Kettering Cancer Center in New York. She currently works as a consultation-liason psychiatrist at White Plains Hospital in White Plains, NY.